Dong-A, Ildong join hands…R&D synergy and resources
By Chon, Seung-Hyun | translator Kang, Shin-Kook
24.05.21 05:09:53
가나다라
0
Dong-A ST made a KRW 25 billion investment into Ildong’s subsidiary Idience…now the second-largest shareholder
Dong-A ST and Idience co-develop novel anticancer drug, Venadaparib
R&D collaboration after co-marketing Motilitone…Idience set to secure a KRW 90 billion financial resource
▲Dong-A ST and Idience sign a strategic equity investment and joint development agreement. Officials, (from left) Ildong Pharmaceutical President Lee Chae-joon, Idience CEO Lee Won-sik, Dong-A ST R&D President Park Jae-hong, and Dong-A ST President Kim Min-youn, taking photos.
Dong-A ST and Idience join hands to develop novel anticancer drugs. Dong-A ST invested KRW 25 billion in Ildong’s subsidiary, Idience, and will co-develop novel anticancer drugs. Consequently, Dong-A ST has secured a pipeline of potential novel anticancer drugs, and Idience successfully contracted investment for its novel drug development.
Dong-A ST invested KRW 25 billion in Idience…strengthens its novel oncology pipeline
According to industry sources on the 20th, Dong-A ST signed a strategic equity investment and joint development agreement with Idience, Ildong’s company specializing in new drug development.
Idience is delivering a third-party allocation
Chon, Seung-Hyun(1000@dailypharm.com)
If you want to see the full article, please JOIN US (click)